Acquist is committed to developing treatment that will better the lives of people with inflammatory diseases.
The Company’s lead programs are in NASH (nonalcoholic steatohepatitis) and gout.
Chronic human illness reflects dysfunction in multiple biological pathways. Given the complexity,
discovery strategies based on “one-target, one-disease” are proving increasingly unsuccessful.
Acquist programs focus on agents that modulate multiple targets simultaneously, as
“bifunctional” or “bispecific” drugs. Addressing cellular functions as a system, rather than a
single-target, may lead to novel classes of effective multi-targeted drugs with fewer side-effects.